A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogenic stem cell transplantation
عنوان الدراسة
A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogenic stem cell transplantation
داعم الدراسة
Novartis
دواء الدراسة
Ruxolitinib (INC424) (Jakavi)
رقم بروتوكول الدراسة
CINC424D2301
حالة الدراسة
Ongoing
موقع الدراسة
KFSH & RC-R
مرحلة الدراسة
3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.